UK Regulatory Body Finds Sanofi in Breach Over Unsubstantiated RSV Therapy Claims Against Pfizer
核心洞察
The UK's Prescription Medicines Code of Practice Authority (搜索) found Sanofi in breach of pharmaceutical industry standards for making unsubstantiated claims about its RSV (搜索) therapy Beyfortus being more effective than Pfizer's Abrysvo vaccine.
The ruling stemmed from a complaint by Pfizer regarding statements made by Sanofi CEO Paul Hudson in an October 2024 Observer newspaper interview, where he claimed clinical benefits favored Beyfortus over maternal vaccination approaches.
The regulatory panel concluded that no direct comparative studies exist to support Sanofi's effectiveness claims, and the company's actions brought discredit to the pharmaceutical industry.
The UK's pharmaceutical industry watchdog has ruled against Sanofi for making unsubstantiated claims about the superiority of its respiratory syncytial virus (搜索) (RSV (搜索)) therapy over Pfizer's competing vaccine, following a formal complaint that highlighted concerns about misleading promotional practices in the industry.
The Prescription Medicines Code of Practice Authority (搜索) (PMCPA (搜索)) found the French drugmaker in breach of UK pharmaceutical standards after investigating statements made by Sanofi CEO Paul Hudson in an October 2024 Observer newspaper interview. The ruling addresses claims that Beyfortus, Sanofi's antibody-based RSV (搜索) preventive therapy developed with AstraZeneca, was more clinically beneficial than Pfizer's Abrysvo vaccine.
Regulatory Findings and Industry Impact
The PMCPA (搜索) panel concluded that Sanofi's actions "brought discredit upon, and reduced confidence in, the pharmaceutical industry." The authority found no evidence, including direct comparative studies, to support claims that Sanofi's therapy was "more effective" than Pfizer's vaccine. The panel noted that Sanofi had later attempted to remove the disputed claim from the article, acknowledging that no head-to-head studies exist between the two products.
Sanofi was found in breach on seven counts under the Association of the British Pharmaceutical Industry (ABPI) code of practice, including making misleading and unsubstantiated claims, disparaging another company's medicines, and providing unbalanced information to the public to encourage requests for a specific prescription-only medicine.
The Disputed Claims
The controversy centered on Hudson's statements in the Observer profile piece, where he referenced data from Spain showing reduced RSV (搜索) hospitalization rates in babies treated with Beyfortus at less than six months of age. Hudson characterized the UK's decision to use Abrysvo as a "financial choice" rather than one based on efficacy, stating: "If you're choosing for a clinical benefit, you would choose Beyfortus."
According to Pfizer's complaint, these statements constituted promotional efficacy claims that violated industry standards, particularly given that some comments referenced data from Spain where Beyfortus is approved for use in normal term newborns, unlike its more limited UK approval.
Different Therapeutic Approaches
Both products serve the RSV (搜索) prevention market but through different mechanisms and patient populations. Abrysvo, which received NHS approval in 2023, is administered to pregnant women typically between 28 to 36 weeks of gestation to protect their infants after birth. Beyfortus, approved in the UK last year, is currently cleared for use in premature babies before 32 weeks and represents a preventive antibody approach to RSV protection.
The regulatory review emphasized that given the prominence of the publication, it was "critical that the global senior leader exercised caution given the interview topics could range from their hobbies on the one hand, to being asked about prescription-only medicines on the other."
Company Responses
Sanofi acknowledged the PMCPA (搜索) ruling in an emailed statement, saying it "accepts the findings" and "remains committed to the highest standards of ethical conduct and responsible external engagement." The company had argued during the review process that some disputed comments were written by the journalist rather than being direct quotes, and that it had requested removal of one claim, which The Observer denied.
Pfizer had initiated an intercompany dialogue with Sanofi about the incident but was unable to resolve the matter before filing the formal complaint that triggered the regulatory investigation.